Company intelligence / Profile preview

Vima Therapeutics

Cambridge, Massachusetts, United Statesvimatx.com ↗

Ownership: Private
Development stage: Phase 1

Overview

Vima Therapeutics has launched with $60 million Series A financing to advance its lead candidate, VIM0423—a potential first-in-class oral small molecule targeting muscarinic cholinergic receptors for isolated dystonia. The drug aims to address the root cause of dystonia and overcome tolerability issues seen with existing therapies. Phase 1 clinical trials are ongoing; Phase 2 initiation expected in late 2025. No clinical results have been published yet.

Therapeutic areas: Neurology
Modalities: Small molecules (oral therapy)
Industry: Biotech

Drug pipeline

1 asset

VIM0423

Partnerships

No major pharma partnerships disclosed as of June 2025.

Beyond the preview

Go deeper on Vima Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Vima Therapeutics.